The use of haematoimmunoablation followed by autologous haematopoietic stem cell transplantation (HSCT) has been applied to the treatment of severe autoimmune disease (AD) over the past several years in around 200 patients. The concept evolved from a need for alternative options for treating severe AD, an observation that patients receiving HSCT for conventional indications and who also had an AD improved and a consensus between involved specialties (1). Animal model data was available to support the concept (2).
Coincidental autoimmune disease and HSCT
This has been reviewed recently (3), but in summary there are now many reports of long term improvement or even remission in AD patients who have received an HSCT for treating a malignancy or aplastic anaemia. Early reports were allogeneic (4), but more recent include autologous (4). There are also reports of recurrence of AD in successful (full chimeric) allogeneic HSCT for rheumatoid arthritis (RA), underlining the subtlety of the immune response (5).
All these case and small series reports are subject to reporting bias, since no systematic retro or prospective data review exists, or is likely to be generated. Often details of AD severity and extent are missing, and the conditioning regimens were far heavier than contemplated for AD alone. Nevertheless, the sometimes long therm remissions recorded especially with RA (6), spurred the investigators on to explore HSCT as treatment for AD alone. The spectrum of coincidental AD has been broad, including rheumatic disorders such as RA, systemic lupus erythaematosus (SLE), systemic sclerosis (SSc) or scleroderma family of disorders and dermato/polymyositis. Other AD's include multiple sclerosis, myasthenia gravis, psoriasis and inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis.
Animal models
Animal model data exist to support the concept of allogeneic and autologous HSCT to treat AD. The limitations are clear, given the fact that intervention may occur before or after clinical manifestations of AD. The alleviation of AD manifestations through HSCT is not surprising, given the degree of immunosuppression involved in the conditioning. However, the most important and hopeful observation from animal studies involved the apparent induction of tolerance in a rat arthritis model to the inciting agent (Freund's adjuvant) following autologous HSCT (7). This supports the hope that in humans an autologous HSCT, clearly less toxic due to lack of graft versus host disease (GVHD) could be sufficient for long term remission.
Autoimmune disease
Most human AD's have the following features in common: 1) Although genetically predisposed, another environmental factor(s) is/are required for disease expression. This is supported by the homozygous twin data, showing concordance rates of 15% for SLE, 18% for RA, 25% for MS and 50% for insulin dependent diabetes mellitus (IDDM). Therefore, an autologous approach may be effective. 2) Most AD's probably have multiple potential triggers, all of which may result in a final common pathway called disease. Clearly self reacting T-cells escape thymic deletion and reside in the periphery where, under suitable conditions such as intercurrent infection, they may be activated and expanded, both precipitating and maintaining AD.
3) The genetics are complex, with only some link with MHC genes. In IDDM, at least 19 other genes on different chromosomes are implicated. 4) By the time of clinical disease expression, the immunophatology has been present for months or even years. Therefore any HSCT based strategy must be based
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Haematopoietic stem cell transplantation in the treatment of autoimmune diseases: current experience from an international data base on a "resetting" of the immune system, rather than an "allor-nothing" approach undertaken in malignant disease.
Clinical experience
The literature contains around 20 case reports of successful HSCT in the treatment of AD, including RA, SLE, MS, juvenile arthritis and SSc. There are no reported deaths associated with either failed treatment or transplant related mortality.
Under the auspices of the European Group for Blood and Marrow Transplantation (EBMT) and the European League Against Rheumatism (EULAR), an international project was initiated in 1995 which quickly included other active groups from USA and Australia.
This data base contains data on 170 transplants for AD from 45 centres in 18 countries, collected from the time of mobilisation, and not just transplantation. The International Bone Marrow Transplant Registry (IBMTR) in Milwaukee data base contains data on around 30 more patients. In the Basel data base, the target disease are: MS-56, SSc-37, JRA-17 (mostly systemic Still's disease). RA-17, SLE-14, and other smaller groups including cryoglobulinaemia, ITP, AIHA, TTP, vasculitis, myasthenia gravis and dermatomyositis.
The procedure related mortality was 8-9%, calculated at one year using a Kaplan Meier calculation with the Greenwood formula correction (8). This is higher than the transplant related mortality (TRM) of <3% for autologous HSCT often quoted in the literature, but similar to a control group of non Hodgkin's lymphoma treated in the same centres during the same period (6%). This could reflect the fact that more involvement of vital organs such as hearth, lung, kidney is present in this group, as opposed to patients with breast cancer.
Treatment regimens
Most centres used one of the four basic regimens recommended at the consensus meeting (1) and available from the stem cell project centre on diskette. Mobilisation with cyclophosphamide (Cy) and G-CSF was most frequent, but around a quarter received mobilisation with G-SCF alone. This was associated with some flare of the AD.
Peripherally harvested HSC's were mostly used, apart from the children in whom bone marrow was harvested. The majority of MS patients underwent conditioning with BEAM plus ATG, and in other disease groups a variety of regimens were employed.
Ex vivo graft product manipulation was performed in three quarters but there is as yet no suggestion that relapse of AD is prevented or delayed by T cell purging. More data is required.
Outcome
Strict standardised data collection on outcome is not available, and is subject to a standardisation process internationally at the moment. It is anticipated that all patients will be registered (either in Basel or the IBMTR) using standard forms post mobilisation by the year 2000. On the data available, it is possible to observe that in about two thirds either stabilisation or improvement of the AD was observed. Follow-up periods are from 4.5 years to weeks. The immune reconstitution after HSCT in AD patients seems to be similar to patients with neoplastic disease. In conclusion, a significant modification of the natural history of several severe AD's has been observed using haematoimmunoablation and HSCT. More data is required to confirm this, given the significant TRM recorded. Patient selection is critical in justifying this approach; ie, only patients with a serious threat to life or vital organ function, and in whom a reasonable residual quality of life is possible if the autoimmune process in controlled should be considered at this stage.
The completion of the recently initiated pilot studies should be followed by international, multicentre, prospective controlled studies to avoid delay in clarifying its correct therapeutic role, if any. The choice of comparator eg. mobilised with Cy+G-csf but not transplanted, other experimental immunosuppressive regimen etc and the coordination of such trials will be the major challenge for involved groups.
